A retrospective study of 60 men with CDK12-altered advanced prostate cancer showed that of the 9 men who received PD-1 inhibitor therapy, 33% had a PSA response and the median PFS was 5.4 months[27,55]. This evidence concerns the gene KLK3 and prostate cancer.